RxDoctor Payments Data

Peter Ohare, MD

Obstetrics & Gynecology · Bel Air, MDNPI 1912160771

Payments from drug & device makers

$5,289in general payments, 2019–2025

Across 100 payments — averaging $52.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Axonics, Inc.$2K
  • Caldera Medical, Inc$562
  • AbbVie$361
  • Sumitomo Pharma America, Inc.$259
  • Medtronic$178
  • plus $641 from 14 others

What the payments were for

  • Speaking & faculty fees$1,27524%
  • Food & beverage$4,01476%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,289 in reported general payments places this provider in the 90th percentile of 842 obstetrics & gynecology providers in Maryland.

See all obstetrics & gynecology providers in Maryland

Medicare billing

Part B allowed, 2024
$140,498
Medicare patients
232
Services billed
925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron25$23,483
MyrbetriqMirabegron34$18,013
Estradiol96$5,563
Solifenacin Succinate13$913
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst23$462
Oxycodone Hcl15$45
Ibuprofen11$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$259$23,48325 claims
Astellas Pharma US IncMyrbetriq$141$18,01334 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 842 obstetrics & gynecology providers in Maryland.

Other obstetrics & gynecology in Bel Air

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →